Association between Bcl-2 expression and tumor recurrence in cervical cancer: A matched case-control study

Gynecologic Oncology

Volumn 102, Issue 2, 2006, Pages 263-269

  Manusirivithaya, Sumonmal ^a   Siriaunkgul, Sumalee ^b   Khunamornpong, Surapan ^b   Sripramote, Manit ^a   Sampatanukul, Pichet ^c   Tangjitgamol, Siriwan ^a   Srisomboon, Jatupol ^b  

^a Bangkok Metropolitan Administration   (Thailand)

^b Faculty of Medicine Chiang Mai University   (Thailand)

^c CHULALONGKORN UNIVERSITY   (Thailand)

Author keywords

bcl 2; Cervical cancer; Prognosis; Radical hysterectomy; Recurrence

Indexed keywords

PARAFFIN; PROTEIN BCL 2;

ADULT; ARTICLE; CANCER GRADING; CANCER RECURRENCE; CANCER SIZE; CANCER TISSUE; CASE CONTROL STUDY; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE FREE INTERVAL; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADICAL HYSTERECTOMY; RISK; THAILAND; UTERINE CERVIX CANCER;

ADULT; CASE-CONTROL STUDIES; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-BCL-2; UTERINE CERVICAL NEOPLASMS;

EID: 33745995485     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2005.12.037     Document Type: Article

References (49)

1. Deerasamee S, Martin N, Sontipong S, Sriamporn S, Sriplung H, Srivatanakul P. et al. Cancer in Thailand. IARC technical report No34, 1999. p. 56.
2. Manusirivithaya S. Gynecologic Oncology Annual Report of BMA Medical College and Vajira Hospital No 3, 2001: 64.
3. Landoni F., Maneo A., Colombo A., Placa F., Milani R., Perego P., et al. Randomised study of radical surgery versus radiotherapy for stage Ib-IIa cervical cancer. Lancet 23 (1997) 535-540
4. Kim S.M., Choi H.S., and Byun J.S. Overall 5-year survival rate and prognostic factors in patients with stage IB and IIA cervical cancer treated by radical hysterectomy and pelvic lymph node dissection. Int. J. Gynecol. Cancer 10 (2000) 305-312
5. Manusirivithaya S., Charoeniam V., Isariyodom P., and Pantusart A. Risk for radical hysterectomy failure. J. Med. Assoc. Thai. 84 (2001) 791-797
6. Burke T.W., Hoskins W.J., Heller P.B., Bibro M.C., Weiser E.B., and Park R.C. Prognostic factors associated with radical hysterectomy failure. Gynecol. Oncol. 26 (1987) 153-159
7. Larson D.M., Copeland L.J., Stringer C.A., Gershenson D.M., Malone Jr. J.M., and Edwards C.L. Recurrent cervical carcinoma after radical hysterectomy. Gynecol. Oncol. 30 (1988) 381-387
8. Estape R.E., Angioli R., Madrigal M., Janicek M., Gomez C., Penalver M., et al. Close vaginal margins as a prognostic factor after radical hysterectomy. Gynecol. Oncol. 68 (1998) 229-232
9. Zreik T.G., Chambers J.T., and Chambers S.K. Parametrial involvement, regardless of nodal status: a poor prognostic factor for cervical cancer. Obstet. Gynecol. 87 5 Pt. 1 (1996) 741-746
10. Kodaira T., Fuwa N., Nakanishi T., Kuzuya K., Sasaoka M., Furutani K., et al. Retrospective analysis of postoperative radiotherapy for node-negative cervical carcinoma with stage IB-IIB disease. Jpn. J. Clin. Oncol. 32 (2002) 255-261
11. Schorge J.O., Molpus K.L., Koelliker D., Nikrui N., Goodman A., and Fuller Jr. A.F. Stage IB and IIA cervical cancer with negative lymph nodes: the role of adjuvant radiotherapy after radical hysterectomy. Gynecol. Oncol. 66 (1997) 31-35
12. Samlal R.A., van der Velden J., Ten Kate F.J., Schilthuis M.S., Hart A.A., and Lammes F.B. Surgical pathologic factors that predict recurrence in stage IB and IIA cervical carcinoma patients with negative pelvic lymph nodes. Cancer 80 (1997) 1234-1240
13. Smiley L.M., Burke T.W., Silva E.G., Morris M., Gershenson D.M., and Wharton J.T. Prognostic factors in stage IB squamous cervical cancer patients with low risk for recurrence. Obstet. Gynecol. 77 (1991) 271-275
14. Koh W.J., Panwala K., and Greer B. Adjuvant therapy for high-risk, early stage cervical cancer. Semin. Radiat. Oncol. 10 (2000) 51-60
15. Tsujimoto Y., Finger L.R., Yunis J., Nowell P.C., and Croce C.M. Cloning of the chromosome breakpoint of neoplastic B cells with the t(14;18) chromosome translocation. Science 226 (1984) 1097-1099
16. Hockenbery D.M., Zutter M., Hickey W., Nahm M., and Korsmeyer S.J. BCL2 protein is topographically restricted in tissues characterized by apoptotic cell death. Proc. Natl. Acad. Sci. U.S.A. 88 (1991) 6961-6965
17. Lu Q.L., Poulsom R., Wong L., and Hanby A.M. Bcl-2 expression in adult and embryonic non-haematopoietic tissues. J. Pathol. 169 (1993) 431-437
18. Hockenbery D., Nunez G., Milliman C., Schreiber R.D., and Korsmeyer S.J. Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 348 6299 (1990) 334-336
19. Vaux D.L., Cory S., and Adams J.M. Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. Nature 335 6189 (1988) 440-442
20. Reed J.C. Bcl-2 and the regulation of programmed cell death. J. Cell Biol. 124 (1994) 1-6
21. Belka C., and Budach W. Anti-apoptotic bcl-2 proteins: structure, function and relevance for radiation biology. Int. J. Radiat. Biol. 78 (2002) 643-658
22. Pillai M., Jayaprakash P., and Nair M. bcl-2 immunoreactivity but not p53 accumulation associated with tumour response to radiotherapy in cervical carcinoma. J. Cancer Res. Clin. Oncol. 125 (1999) 55-60
23. Rajkumar T., Rajan S., Baruah R.K., Majhi U., Selvaluxmi G., and Vasanthan A. Prognostic significance of Bcl-2 and p53 protein expression in stage IIB and IIIB squamous cell carcinoma of the cervix. Eur. J. Gynaecol. Oncol. 19 (1998) 556-560
24. Wootipoom V., Lekhyananda N., Phungrassami T., Boonyaphiphat P., and Thongsuksai P. Prognostic significance of Bax, Bcl-2, and p53 expressions in cervical squamous cell carcinoma treated by radiotherapy. Gynecol. Oncol. 94 (2004) 636-642
25. Dimitrakakis C., Kymionis G., Diakomanolis E., Papaspyrou I., Rodolakis A., Arzimanoglou I., et al. The possible role of p53 and bcl-2 expression in cervical carcinomas and their premalignant lesions. Gynecol. Oncol. 77 (2000) 129-136
26. Tjalma W., Weyler J., Goovaerts G., De Pooter C., Van Marck E., and van Dam P. Prognostic value of bcl-2 expression in patients with operable carcinoma of the uterine cervix. J. Clin. Pathol. 50 (1997) 33-36
27. Padovan P., Salmaso R., Marchetti M., and Padovan R. Prognostic value of bcl-2, p53 and Ki-67 in invasive squamous carcinoma of the uterine cervix. Eur. J. Gynaecol. Oncol. 21 (2000) 267-272
28. Saito T., Takehara M., Tanaka R., Lee R., Horie M., Wataba K., et al. Correlation between responsiveness of neoadjuvant chemotherapy and apoptosis-associated proteins for cervical adenocarcinoma. Gynecol. Oncol. 92 (2004) 284-292
29. Ishida H., Irie K., Itoh T., Furukawa T., and Tokunaga O. The prognostic significance of p53 and bcl-2 expression in lung adenocarcinoma and its correlation with Ki-67 growth fraction. Cancer 80 (1997) 1034-1045
30. Nakanishi H., Ohsawa M., Naka N., Uchida A., Ochi T., and Aozasa K. Immunohistochemical detection of bcl-2 and p53 proteins and apoptosis in soft tissue sarcoma: their correlations with prognosis. Oncology 54 (1997) 238-244
31. Hwang T.S., Han H.S., Choi H.K., Lee Y.J., Kim Y.J., Han M.Y., et al. Differential, stage-dependent expression of Hsp70, Hsp110 and Bcl-2 in colorectal cancer. J. Gastroenterol. Hepatol. 18 (2003) 690-700
32. Erdem O., Erdem M., Dursun A., Akyol G., and Erdem A. Angiogenesis, p53, and bcl-2 expression as prognostic indicators in endometrial cancer: comparison with traditional clinicopathologic variables. Int. J. Gynecol. Pathol. 22 (2003) 254-260
33. Yang Q., Sakurai T., Yoshimura G., Suzuma T., Umemura T., Nakamura M., et al. Prognostic value of Bcl-2 in invasive breast cancer receiving chemotherapy and endocrine therapy. Oncol. Rep. 10 (2003) 121-125
34. Khabir A., Ghorbel A., Daoud J., Frikha M., Drira M.M., Laplanche A., et al. Similar BCL-X but different BCL-2 levels in the two age groups of north African nasopharyngeal carcinomas. Cancer Detect. Prev. 27 (2003) 250-255
35. Lee H.K., Lee H.S., Yang H., Kim W.H., Lee K.U., Choe K.J., et al. Prognostic significance of Bcl-2 and p53 expression in gastric cancer. Int. J. Colorectal. Dis. 18 (2003) 518-525
36. Bukholm I.R., Bukholm G., and Nesland J.M. Reduced expression of both Bax and Bcl-2 is independently associated with lymph node metastasis in human breast carcinomas. APMIS 110 (2002) 214-220
37. Uehara T., Kuwashima Y., Izumo T., Kishi K., Shiromizu K., and Matsuzawa M. Expression of the proto-oncogene bcl-2 in uterine cervical squamous cell carcinoma: its relationship to clinical outcome. Eur. J. Gynaecol. Oncol. 16 (1995) 453-460
38. Graflund M., Sorbe B., and Karlsson M. Immunohistochemical expression of p53, bcl-2, and p21(WAF1/CIP1) in early cervical carcinoma: correlation with clinical outcome. Int. J. Gynecol. Cancer 12 (2002) 290-298
39. Ozalp S.S., Yalcin O.T., Tanir H.M., Dundar E., and Yildirim S. Bcl-2 expression in preinvasive and invasive cervical lesions. Eur. J. Gynaecol. Oncol. 23 (2002) 419-422
40. Crawford R.A., Caldwell C., Iles R.K., Lowe D., Shepherd J.H., and Chard T. Prognostic significance of the bcl-2 apoptotic family of proteins in primary and recurrent cervical cancer. Br. J. Cancer 78 (1998) 210-214
41. Tjalma W., De Cuyper E., Weyler J., Marck E.V., De Pooter C., Albertyn G., et al. Expression of bcl-2 in invasive and in situ carcinoma of the uterine cervix. Am. J. Obstet. Gynecol. 178 1 Pt. 1 (1998) 113-117
42. Tjalma W.A., Weyler J.J., Bogers J.J., Pollefliet C., Baay M., Goovaerts G.C., et al. The importance of biological factors (bcl-2, bax, p53, PCNA, MI, HPV and angiogenesis) in invasive cervical cancer. Eur. J. Obstet. Gynecol. Reprod. Biol. 97 (2001) 223-230
43. Harima Y., Harima K., Shikata N., Oka A., Ohnishi T., and Tanaka Y. Bax and Bcl-2 expressions predict response to radiotherapy in human cervical cancer. J. Cancer Res. Clin. Oncol. 124 (1998) 503-510
44. Harima Y., Nagata K., Harima K., Oka A., Ostapenko V.V., Shikata N., et al. Bax and Bcl-2 protein expression following radiation therapy versus radiation plus thermoradiotherapy in stage IIIB cervical carcinoma. Cancer 88 (2000) 132-138
45. Jain D., Srinivasan R., Patel F.D., and Kumari Gupta S. Evaluation of p53 and Bcl-2 expression as prognostic markers in invasive cervical carcinoma stage IIb/III patients treated by radiotherapy. Gynecol. Oncol. 88 (2003) 22-28
46. Ohsaki Y., Toyoshima E., Fujiuchi S., Matsui H., Hirata S., Miyokawa N., et al. bcl-2 and p53 protein expression in non-small cell lung cancers: correlation with survival time. Clin. Cancer Res. 2 (1996) 915-920
47. Ilyas M., Hao X.P., Wilkinson K., Tomlinson I.P.M., Abbasi A.M., Forbes A., et al. Loss of Bcl-2 expression correlates with tumour recurrence in colorectal cancer. Gut 43 (1998) 383-387
48. Athanassiadou P., Petrakakou E., Liossi A., Nakopoulou L., Zerva C., Dimopoulos A., et al. Prognostic significance of p53, bcl-2 and EGFR in carcinoma of the endometrium. Acta Cytol. 43 (1999) 1039-1044
49. Aletra C., Ravazoula P., Scopa C., Kounelis S., Sotiropoulou G., Kourounis G., et al. Expression of bcl-2 and bax in cervical intraepithelial neoplasia and invasive squamous cell carcinoma of the uterine cervix. Eur. J. Gynaecol. Oncol. 21 (2000) 494-498